Vycor Medical, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020
August 17, 2020 at 06:33 am EDT
Share
Vycor Medical, Inc. announced earnings results for the second quarter ended June 30, 2020. For the second quarter, the company announced sales was USD 244,266 compared to USD 411,902 a year ago. Operating loss was USD 199,358 compared to USD 130,545 a year ago. Net loss was USD 248,887 compared to USD 185,304 a year ago. Basic loss per share was USD 0.01 compared to USD 0.01 a year ago. For the half year, sales was USD 574,505 compared to USD 738,509 a year ago. Operating loss was USD 346,059 compared to USD 260,094 a year ago. Net loss was USD 423,835 compared to USD 365,602 a year ago. Basic loss per share was USD 0.02 compared to USD 0.02 a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.01 a year ago.
Vycor Medical, Inc. provides surgical and therapeutic solutions. The Company designs, develops and markets neurological medical devices and therapies. The Company operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment designs, develops and markets medical devices for use in neurosurgery. The NovaVision segment provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage such as that caused by a stroke. Vycor Medical's product Vycor Medical's ViewSite Brain Access System (VBAS) is a next generation retraction and access system. Vycor Medical focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals. NovaVision's products include Vision Restoration Therapy (VRT), NeuroEyeCoach and Neuro-Eye Therapy (NeEt). The Company operates in the United States and Europe.
VYCOR MEDICAL, INC. 
